The U.S. Food and Drug Administration has approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. Treatment with Kisunla should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was studied in the clinical trials. Dr. Pauldurai will talk about the new drug, benefits, and answer questions you may have about it.

Please register and you will receive Zoom information prior to the class.

Presenter
Dr. Jennifer Pauldurai, MD
Dr. Jennifer Pauldurai is a specialty care physician board certified in neurology and board eligible in neuropsychiatry at Inova Health System. She joined Inova in 2023 and has been practicing since 2019. Prior to joining Inova, Dr. Pauldurai was a behavioral neurology and neuropsychiatry fellow at Lou Ruvo Center for Brain Health, Cleveland Clinic in Las Vegas. Dr. Pauldurai’s clinical areas of interest include memory disorders, dementia syndromes, behavioral disruptions including hallucinations and delusions, and mood disorders in the setting of neurodegenerative disease.

 
Sign Me Up!